Opendata, web and dolomites

TruVue

A novel and easy to interpret patient safety monitor, for the diagnosis and management of cardiac function, fluid delivery and drug administration during surgery and intensive care.

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 TruVue project word cloud

Explore the words cloud of the TruVue project. It provides you a very rough idea of what is the project "TruVue" about.

simply    blood    meet    seed    population    pressure    truly    velocity    thousands    lifespan    deltex    stroke    costed    surgery    234    diagnostic    faces    trial    revenues    failing    unplanned    51    patients    obtain    admissions    ages    loops    protecting    graphical    stay    die    provides    adverse    kidney    instability    infarctions    presented    aortic    full    hemodynamic    unacceptable    million    centres    simultaneous    marked    intensive    save    input    multinational    worldwide    enter    errors    undergo    frequent    interaction    healthcare    annually    hospital    inadequate    monitoring    13    complications    mortality    myocardial    flow    readmissions    days    discharge    injury    business    globally    safety    care    generate    publications    haemodynamic    contribution    visual    plan    display    paris    investment    truvue    financial    ce    monitors    serious    events    outcomes    patient    fold    lives    2020    sooner    uses    reduce    clinical    situation    day    sales    42    12    longer    shorter    gui    lariboisiere    interface    opportunity    multicentre    envisages    return   

Project "TruVue" data sheet

The following table provides information about the project.

Coordinator
DELTEX MEDICAL LIMITED 

Organization address
address: TERMINUS ROAD
city: CHICHESTER
postcode: PO19 8TX
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country United Kingdom [UK]
 Project website http://www.deltexmedical.com
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.2.1.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies - Information and Communication Technologies (ICT))
2. H2020-EU.2.3.1. (Mainstreaming SME support, especially through a dedicated instrument)
 Code Call H2020-SMEINST-1-2016-2017
 Funding Scheme SME-1
 Starting year 2017
 Duration (year-month-day) from 2017-06-01   to  2017-11-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    DELTEX MEDICAL LIMITED UK (CHICHESTER) coordinator 50˙000.00

Map

 Project objective

Worldwide 234 million patients undergo major surgery annually. One million will die within 30 days. A further 42 million simply die up to 13 years sooner due to complications and 12 million will enter intensive care in the EU and US. This unacceptable situation has the potential to increase Deltex’s revenues 5 fold by 2020 through the development of TruVue. Of the adverse events 51% are directly due to inadequate haemodynamic management. Hemodynamic instability and low blood pressure are frequent, with consequences such as myocardial infarctions, stroke and kidney injury. Complications have serious clinical and financial consequences; unplanned intensive care admissions; longer stay; increased readmissions; increased 30 day mortality; and shorter patient lifespan after discharge. Healthcare faces increasingly complex cases as the population ages and uses ever more complex equipment. Protecting patients from haemodynamic errors through improved monitoring should save thousands of lives, improve outcomes and reduce costs. Diagnostic haemodynamic equipment needs to display the interaction of flow and pressure if it is to be truly effective. Current monitors are failing to meet this need. Deltex and Lariboisiere Hospital Paris have developed the novel TruVue Velocity Pressure Loops system. TruVue provides simultaneous visual display of the patient’s aortic blood flow velocity and aortic blood pressure; and will be a significant contribution to patient safety. TruVue has been CE-marked and is in use at Lariboisiere Hospital. This phase 1 project has two aims: to obtain user input to enhance the Graphical User Interface (GUI); and to cost a multinational multicentre clinical trial for phase 2 application. Deltex envisages that the clinical trial will generate publications, ‘seed’ leading centres and promote the TruVue within the EU and globally. A full assessment of the sales opportunity and return on investment will be presented as part of a fully-costed business plan.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "TRUVUE" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "TRUVUE" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.2.1.1.;H2020-EU.2.3.1.)

SOFT (2017)

SOFT, the first camera-based colorectal cancer screening test to detect occult blood in faeces immediately and with no lab analysis.

Read More  

Assist (2015)

Telocate ASSIST – Development and marketing of an acoustic solution for localization and navigation of people in buildings using the smartphone

Read More  

Leaf Line (2018)

The First Global Ground Station Network to Fully Exploit Microsatellites Data

Read More